PL3173071T3 - Formulacja maropitantu - Google Patents

Formulacja maropitantu

Info

Publication number
PL3173071T3
PL3173071T3 PL16200848T PL16200848T PL3173071T3 PL 3173071 T3 PL3173071 T3 PL 3173071T3 PL 16200848 T PL16200848 T PL 16200848T PL 16200848 T PL16200848 T PL 16200848T PL 3173071 T3 PL3173071 T3 PL 3173071T3
Authority
PL
Poland
Prior art keywords
maropitant
formulation
maropitant formulation
Prior art date
Application number
PL16200848T
Other languages
English (en)
Inventor
Marinus Maria Martinus Boeren
Rudolf Johannes Paridaans
Original Assignee
Le Vet B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57460319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3173071(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Le Vet B.V. filed Critical Le Vet B.V.
Publication of PL3173071T3 publication Critical patent/PL3173071T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16200848T 2015-11-27 2016-11-28 Formulacja maropitantu PL3173071T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2015865A NL2015865B1 (en) 2015-11-27 2015-11-27 Maropitant Formulation.
EP16200848.6A EP3173071B1 (en) 2015-11-27 2016-11-28 Maropitant formulation

Publications (1)

Publication Number Publication Date
PL3173071T3 true PL3173071T3 (pl) 2021-08-16

Family

ID=57460319

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16200848T PL3173071T3 (pl) 2015-11-27 2016-11-28 Formulacja maropitantu

Country Status (12)

Country Link
EP (1) EP3173071B1 (pl)
CY (1) CY1124893T1 (pl)
DK (1) DK3173071T3 (pl)
ES (1) ES2873376T3 (pl)
HR (1) HRP20210986T1 (pl)
HU (1) HUE054584T2 (pl)
LT (1) LT3173071T (pl)
NL (1) NL2015865B1 (pl)
PL (1) PL3173071T3 (pl)
PT (1) PT3173071T (pl)
RS (1) RS62057B1 (pl)
SI (1) SI3173071T1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3609495A4 (en) 2017-04-10 2020-12-02 Chase Therapeutics Corporation NK1 ANTAGONIST COMBINATION AND METHOD OF TREATMENT OF SYNUCLEINOPATHIA
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6340166A (ja) 1986-08-06 1988-02-20 Fuji Xerox Co Ltd 電子写真感光体
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
JP5021318B2 (ja) 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
JP4951344B2 (ja) 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
EP3446692A1 (en) 2011-11-29 2019-02-27 Jurox Pty. Ltd. Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物

Also Published As

Publication number Publication date
SI3173071T1 (sl) 2021-11-30
EP3173071B1 (en) 2021-03-24
HUE054584T2 (hu) 2021-09-28
EP3173071A1 (en) 2017-05-31
NL2015865B1 (en) 2017-06-13
DK3173071T3 (da) 2021-06-28
LT3173071T (lt) 2021-07-12
HRP20210986T1 (hr) 2021-09-17
RS62057B1 (sr) 2021-07-30
CY1124893T1 (el) 2023-01-05
ES2873376T3 (es) 2021-11-03
PT3173071T (pt) 2021-04-15

Similar Documents

Publication Publication Date Title
HK1256195A1 (zh) 穩定的抗ifnar1配製品
GB201513010D0 (en) Novel formulation
GB201407934D0 (en) Formulation
GB201514758D0 (en) Formulation
GB201608356D0 (en) Formulation
RS62057B1 (sr) Formulacija maropitanta
IL248835B (en) A preparation of ciritinib
GB201407384D0 (en) Formulation
IL251362A0 (en) formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201707615D0 (en) Formulation
GB201511301D0 (en) Formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201609925D0 (en) Formulation
GB201514014D0 (en) Formulation
GB201602048D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation